Drug Trial Radar · NCT04527991
Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
711
Actual
Start
Jan 13, 2021
Primary completion
Jul 4, 2025
Study completion Jul 4, 2025
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Aug 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess overall survival (OS) with sacituzumab govitecan-hziy in comparison with treatment of physician's choice (TPC) in participants with metastatic or locally advanced unresectable urothelial cancer (UC).
Conditions
- Locally Advanced or Metastatic Unresectable Urothelial Cancer
Interventions
Sacituzumab Govitecan-hziyDrug
Administered intravenously
PaclitaxelDrug
Administered intravenously
DocetaxelDrug
Administered intravenously
VinflunineDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to 42 months
Locations
234 sites in 27 countries. Site status is shown where the registry gives one.
Mayo Clinic - Arizona
Phoenix, Arizona
UCLA Hematology/ Oncology
Los Angeles, California
University of California Irvine (UCIMC)
Orange, California
MedStar Washington Hospital Center
Washington D.C., District of Columbia
Baptist MD Anderson Cancer Center
Jacksonville, Florida
Boca Raton Clinical Research Global USA - Plantation
Plantation, Florida
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Maryland School of Medicine
Baltimore, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Roswell Park Cancer Institute
Buffalo, New York
Weill Cornell Medical College
New York, New York
Montefiore Medical Center
The Bronx, New York
Cleveland Clinic
Cleveland, Ohio
Oklahoma Cancer Specialists and Research Institute (OCSRI)
Tulsa, Oklahoma
Penn State Hershey Cancer Institute
Hershey, Pennsylvania
Thompson Oncology Group - Knoxville Downtown
Knoxville, Tennessee
University Cancer Specialists - Knoxville
Knoxville, Tennessee
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas
Center for Cancer and Blood Disorders
Fort Worth, Texas
Seattle Cancer Care Alliance (SCCA)
Seattle, Washington
Summit Cancer Centers
Spokane, Washington
Chris O'Brien Lifehouse
North Ryde, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Icon Cancer Centre Wesley
Auchenflower, Queensland, Australia
Southern Adelaide Local Health Network Incorporated
Bedford Park, South Australia, Australia
Ashford Cancer Centre Research - ICON Cancer Centre Adelaide
Kurralta Park, South Australia, Australia
ICON Cancer Centre Hobart
Hobart, Tasmania, Australia
Monash Health
Clayton, Victoria, Australia
Austin Health
Heidelberg, Victoria, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Sunshine Hospital
Saint Albans, Victoria, Australia
Liverpool Hospital
Nedlands, Western Australia, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
Universitätsklinik für Innere Medizin Graz
Graz, Austria
Ordensklinikum Linz GmbH Barmherzige Schwestern
Linz, Austria
Krankenhaus Der Barmherzigen Bruder Wien
Vienna, Austria
Grand Hôpital De Charleroi - Notre Dame
Charleroi, Belgium
Az Maria Middelares Ghent
Ghent, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Showing 40 of 234 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.